Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Account Payables: 2015-2024

Historic Change in Account Payables for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $1.1 million.

  • Apellis Pharmaceuticals' Change in Account Payables fell 1250.43% to -$15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 92.11%. This contributed to the annual value of $1.1 million for FY2024, which is 540.59% up from last year.
  • Apellis Pharmaceuticals' Change in Account Payables amounted to $1.1 million in FY2024, which was up 540.59% from $170,000 recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Account Payables registered a high of $18.7 million during FY2022, and its lowest value of -$54,000 during FY2020.
  • For the 3-year period, Apellis Pharmaceuticals' Change in Account Payables averaged around $6.6 million, with its median value being $1.1 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Change in Account Payables skyrocketed by 19,520.37% in 2021 and then tumbled by 99.09% in 2023.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Change in Account Payables stood at -$54,000 in 2020, then skyrocketed by 19,520.37% to $10.5 million in 2021, then surged by 78.21% to $18.7 million in 2022, then crashed by 99.09% to $170,000 in 2023, then spiked by 540.59% to $1.1 million in 2024.